Goyal Hemant, Perisetti Abhilash, Rehman M Rubayat, Singla Umesh
Department of Internal Medicine, Mercer University School of Medicine.
Department of Family and Community Medicine, Texas Tech University, Lubbock, Texas, USA.
Eur J Gastroenterol Hepatol. 2018 Jun;30(6):589-597. doi: 10.1097/MEG.0000000000001103.
Clostridium difficile infection (CDI) represents one of the most serious nosocomial infections that have grown dramatically over the past decade. Vancomycin and metronidazole are currently used as a standard therapy for CDI. Metronidazole is recommended as a first-line therapy for mild-to-moderate infections and vancomycin is mainly used for severe and/or refractory cases. However, studies have demonstrated that there are quite high CDI relapse rates with both of these medications, which represents a challenge for clinicians. Over the last decade, a number of newer and novel therapeutic options have emerged as promising alternatives to these standard CDI therapies. The following review provides the updated summaries of these newer therapeutic agents and their status in the treatment of CDI.
艰难梭菌感染（CDI）是过去十年中急剧增加的最严重的医院感染之一。万古霉素和甲硝唑目前用作CDI的标准疗法。甲硝唑被推荐为轻至中度感染的一线治疗药物，万古霉素主要用于重度和/或难治性病例。然而，研究表明，这两种药物的CDI复发率都相当高，这对临床医生来说是一个挑战。在过去十年中，一些更新颖的治疗选择已成为这些标准CDI疗法的有前景的替代方案。以下综述提供了这些新型治疗药物的最新总结及其在CDI治疗中的地位。
